Novavax shares spurt 35% afterhours as its Covid vaccine shows 89% efficacy  - Kalkine Media

January 29, 2021 12:53 PM GMT | By Kunal Sawhney
Follow us on Google News:

Summary

  • Novavax share price soared more than 35 per cent after-hours on Nasdaq after vaccine indicated promising efficacy results.
  • The stock of Novavax has already registered a gain of more than 1,800 per cent in the last 12 months.

Shares of Novavax Inc (NASDAQ: NVAX), the Maryland-headquartered vaccine maker, have advanced a little more than 35 per cent after its Covid-19 vaccine demonstrated 89 per cent efficacy. The efficacy of the vaccine has been recorded for the Phase 3 trials in the UK with 50 per cent of the cases attributable to newly-mutated virus and the rest to the pre-existing coronavirus.  

(Image Source: © Kalkine Group 2021)

Shares witness heavy flight 

Following the course of development, the shares of Novavax soared as much as 35.06 per cent on Friday, 29 January, to an after-hours high of $181 per share from the market price of $134.01 apiece. With such a massive spike in the share prices of Novavax, it will be pivotal to witness the opening at a time when the futures linked to benchmark indices are trading in the negative territory. 

According to the data available with Nasdaq, the stock of Novavax touched an after-hours low of $111 on Friday, 29 January. Novavax share price has been on a rising run right after realising a bottom during the Covid-led crash. As on the basis of the closing price of 28 January 2021, the stock of Novavax stands with a cumulative yearly gain of more than 1,800 per cent.  

Fourth vaccine in the UK 

The Covid vaccine being developed by Novavax, NVX-CoV2373, is essentially a protein-based vaccine shot. The Novavax Covid vaccine has been formulated from the available genetic sequence of SARS-CoV-2 virus. The vaccine has been undergoing various studies pertaining to its efficacy and adverse effects in the Phase 3 trials in the UK and PREVENT-19 trial in the US and Mexico.  

The protein-based vaccine has an efficacy of 89.3 per cent in the Phase 3 clinical trials held in the UK in partnership with the UK government’s Vaccines Taskforce. The clinical study conducted on the virus vaccine candidate of Novavax includes the efficacy assessment with the mutated virus strain during a period of high transmission.  

The study administered in the Phase 3 clinical trials in the UK enrolled over 15,000 volunteers with nearly 27 per cent of the participants over the age of 65 years from the age group of between 18 and 84 years. The first interim analysis of the vaccine is based on 62 volunteers, of which 32 people were found infected with the new variant of virus, 24 with a non-variant and 6 unknowns.  

The efficacy of the vaccine was calculated to be 95.6 per cent against the original strain of coronavirus and 85.6 per cent against the mutated variant of virus first identified in the UK.  Additionally, the efficacy of the vaccine candidate has arrived at more than 90 per cent in the clinical Phase 2b trials in South Africa. The Novavax vaccine can be stored at temperatures between 2°C and 8°C.  

The vaccine being developed by Novavax is the first vaccine that has shown significant and high clinical efficacy against the newly emerged variants of the virus in the UK and South Africa, said Stanley C. Erck, President and chief executive at the pharma major.  


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.



Top LSE Listed Companies